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Simple Summary: Abiraterone acetate and enzalutamide are novel therapies used in advanced
prostate cancer. However, their outcomes and toxicities may differ based on patient–specific factors.
Understanding these differences may allow clinicians to make personalized treatment decisions
based on individual patients. Because clinical trials do not represent the real-world population, this
study used a formal protocol to review and collate smaller, real-world samples, aiming to explain the
differences in outcomes following administration of these two drugs. We found that enzalutamide
typically has improved cancer response and overall survival. Enzalutamide more commonly causes
neurological side effects and fatigue, while abiraterone acetate has cardiovascular complications.
Abiraterone acetate leads to increased costs and healthcare needs, including hospitalizations and
emergency room visits. Ultimately, this study demonstrates significant differences in patient experiences and outcomes following abiraterone acetate versus enzalutamide. Clinicians may use this
information to inform their treatment choice on a patient-specific basis.
Abstract: Abiraterone acetate (AA) and enzalutamide (ENZ) are commonly used for metastatic
prostate cancer. It is unclear how their outcomes and toxicities vary with patient-specific factors
because clinical trials typically exclude patients with significant comorbidities. This study aims
to fill this knowledge gap and facilitate informed treatment decision making. A registered protocol utilizing PRISMA scoping review methodology was utilized to identify real-world studies. Of
433 non-duplicated publications, 23 were selected by three independent reviewers. ENZ offered a
faster and more frequent biochemical response (30–50% vs. 70–75%), slowed progression (HR 0.66;
95% CI 0.50–0.88), and improved overall survival versus AA. ENZ was associated with more fatigue and neurological adverse effects. Conversely, AA increased risk of cardiovascular- (HR 1.82;
95% CI 1.09–3.05) and heart failure-related (HR 2.88; 95% CI 1.09–7.63) hospitalizations. Ultimately,
AA was associated with increased length of hospital stay, emergency department visits, and hospitalizations (HR 1.26; 95% CI 1.04–1.53). Accordingly, total costs were higher for AA, although pharmacy
costs alone were higher for ENZ. Existing data suggest that AA and ENZ have important differences
in outcomes including toxicities, response, disease progression, and survival. Additionally, adherence, healthcare utilization, and costs differ. Further investigation is warranted to inform treatment
decisions which optimize patient outcomes.
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1. Introduction
Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer in men, accounting for over 20% of new cancer cases [1–4]. Abiraterone acetate (AA), an androgen
biosynthesis inhibitor, and enzalutamide (ENZ), an androgen receptor signaling inhibitor,
are novel hormonal therapies (NHTs) that are mainstay additions to androgen deprivation
therapy in PCa, particularly in metastatic disease [5–10]. Although the survival rate for
locoregional disease approaches 99%, that of advanced and metastatic cancers is markedly
lower, making NHT optimization crucial to urologic oncology [1]. There are currently no
clinical guidelines for choosing AA versus ENZ, and both are approved for use in largely
similar conditions.
Unfortunately, NHT clinical trials frequently exclude patients with significant comorbidities, restricting the generalizability of their findings to the broader population [11]. By
understanding real-world outcomes based on disease-specific measures, drug-associated
toxicities, patient comorbidities, and broader systemic factors, clinicians can perform an
informed risk assessment to guide treatment choice and optimize the patient experience.
Notably, AA and ENZ have primarily been compared in small, retrospective cohorts, which
are limited in interpretation but offer real-world data, the compilation of which may offer
great clinical insight [2].
No adequately powered comparative studies have yet elucidated the real-world risks
and benefits of AA versus ENZ. Understanding potential differences in patient survival
and cancer response rates may improve PCa outcomes. Furthermore, understanding
factors such as patient adherence, healthcare resource utilization (HRU), and total costs
can facilitate quality improvement. Given the availability of alternative treatment options,
tailored therapy has the potential to improve treatment outcomes.
Importantly, adverse drug effects (ADEs) are common with NHTs and may vary with
patient and drug characteristics [8]. Limited real-world studies have shown associations
between NHT toxicities and pre-existing metabolic, cardiovascular, or neurological conditions [12,13]. For instance, AA has been shown to significantly increase cardiomyopathy
while ENZ increases hypertension [11,13–19]. Notably, cardiovascular disease (CVD) is the
most common comorbidity and cause of death in men with PCa, and CVD incidence is
higher in men with PCa compared to the general population, making treatment evaluation
markedly germane to this cohort [1,19]. However, because differential toxicities of AA
and ENZ and their interactions with patient co-morbidities have not been fully elucidated,
there is little guidance on how to choose these drugs based on pre-existing conditions.
This scoping review aims to describe the differential outcomes, ADEs, and systemic
costs of AA and ENZ for metastatic castration-resistant PCa (mCRPC) in a real-world
population. The findings of this review may guide future clinical studies and ultimately
facilitate tailored treatment based on the health condition of the patient.
2. Materials and Methods
The scoping review followed the framework outlined by the Joanna Briggs Institute
Manual for Evidence Synthesis (JBIMES), incorporating protocols established by Arksey
and O’Malley along with revisions from Levac et al. and Peters et al. [20–24]. The study
included the following six steps: defining the research question; identifying relevant studies;
study selection; charting the data; collating, summarizing, and reporting the results; and
consultation. Findings were reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines, utilizing the extension for
scoping reviews (PRISMA-ScR) [25] and the PRISMA-ScR checklist. The study protocol
was registered prior to commencement at Figshare, available at https://doi.org/10.6084/
m9.figshare.19149227.v3 (accessed on 28 June 2022) [26].
2.1. Study Scope
The study was intended to evaluate patient outcomes following AA and ENZ utilizing
data on drug-associated toxicities, mortality, hospitalizations, HRU, costs, patient adher-
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ence, and patient comorbidities. The definition of outcomes was purposefully left broad,
as a variety of disease-specific, patient-reported, and systemic outcomes are important
to clinical decision making. The review focused on real-world cohort studies to create
an analysis applicable to the general population. Studies with rigorous patient exclusion
criteria, such as clinical trials, were excluded.
2.2. Search Strategy
The search strategy for this review was informed by prior PCa therapy research, as well
as recommendations by Tawfik et al. to adapt searches to the database being utilized [27]. An
experienced search librarian was consulted. Searches of PubMed, Cochrane Library, CINAHL,
and Scopus were conducted using the following keywords: “prostate cancer”, “prostatic
neoplasms”, “abiraterone acetate”, “enzalutamide”, “toxicities”, outcomes”, and associated
MeSH terms. These terms were combined with the Boolean operators “AND” and “OR”. The
initial search was performed in PubMed using relevant MeSH terms, and similar searches
were used for Cochrane Library and CINAHL, which also utilize MeSH terms. Only keywords
were used for Scopus. The final search strings are provided in Table 1.
Table 1. Search strings utilized.
Database

Search String

Result

PubMed

(“Prostatic Neoplasms”[MeSH Terms] OR “Prostatic Neoplasms”[All Fields] OR “prostate
cancer”[All Fields]) AND (“Abiraterone Acetate”[MeSH Terms] OR “Abiraterone Acetate”[All
Fields]) AND (“enzalutamide”[All Fields] OR “Androgen signaling inhibitor”[All Fields]) AND
(“Drug-Related Side Effects and Adverse Reactions”[MeSH Terms] OR “Treatment
Outcome”[MeSH Terms] OR “Hospitalization”[MeSH Terms] OR “Mortality”[MeSH Terms] OR
“Comorbidity”[Mesh])

169

Scopus

TITLE-ABS-KEY ((“Prostatic Neoplasms” OR “prostate cancer”) AND (“Abiraterone Acetate”)
AND (enzalutamide OR “Androgen signaling inhibitor”) AND (“Drug-Related Side Effects and
Adverse Reactions” OR “Treatment Outcome” OR hospitalization OR mortality OR comorbidity))
AND (LIMIT-TO (DOCTYPE, “ar”) OR LIMIT-TO (DOCTYPE, “re”) OR LIMIT-TO (DOCTYPE,
“no”)) AND (LIMIT-TO (LANGUAGE, “English”))

399

CINAHL

((MH “Prostatic Neoplasms+”) OR “Prostatic Neoplasms” OR “prostate cancer”) AND ((MH
“Abiraterone Acetate+”) OR “Abiraterone Acetate”) AND (enzalutamide OR “Androgen
signaling inhibitor”) AND ((MH “Drug-Related Side Effects and Adverse Reactions+”) OR
(MH “Treatment Outcome+”) OR (MH Hospitalization+) OR (MH Mortality+) OR
(MH Comorbidity+))

3

Cochrane Reviews

([mh “Prostatic Neoplasms”] OR “Prostatic Neoplasms” OR “prostate cancer”) AND ([mh
“Abiraterone Acetate”] OR “Abiraterone Acetate”) AND (enzalutamide OR “Androgen signaling
inhibitor”) AND ([mh “Drug-Related Side Effects and Adverse Reactions”] OR [mh “Treatment
Outcome”] OR [mh Hospitalization] OR [mh Mortality] OR [mh Comorbidity])

0

The search was restricted to full-length peer-reviewed English publications through
31 January 2022. Free-standing abstracts, opinion pieces, reviews, and letters to the editor
were excluded. Due to their abbreviated format, abstracts do not present all relevant data,
while editorials are opinion-based.
This review captured studies that compared outcomes and toxicities of AA and ENZ,
focusing on retrospective institutional or population-based cohort studies. Studies investigating only one of the treatments were also excluded. If further information was required,
the respective authors of the publications were contacted. The reference lists of all included
articles were also searched for additional studies.
2.3. Data Charting and Extraction Process
Endnote 20 (Clarivate, Philadelphia, PA, USA) was employed for imported reference
management and duplication removal. Studies identified by the above search strategy to
satisfy the initial inclusion criteria were considered for title, abstract, and keyword screening
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by three independent reviewers. Articles satisfying initial screening underwent full-text
screening by three independent reviewers. Lack of unanimity regarding determination of
study eligibility at each stage was resolved through discussion with a senior member of the
research team.
Three members of the research team (YBS, JB, and SM) independently conducted data
extraction. From each article, the following information was extracted: author, year of
publication, title, drug treatment regimen, study type/design, study population, primary
objective(s), outcome(s), and primary conclusions (Table 2).
2.4. Synthesis, Reporting of Results, and Consultation
Given the broad scope of the research question and wide-ranging definition of patient
outcomes and limited availability of published real-world cohort studies, a narrative
synthesis and reporting of results was chosen. Extracted outcomes were wide-ranging
in context and form, making a systematic review and meta-analysis suboptimal. Expert
clinicians (WKK and SJF), who serve as the primary stakeholders in the determinations
of this study, were consulted to inform data interpretation and subsequent discussion of
clinical implications.
3. Results
3.1. Selection of Sources
The systematized literature search retrieved 571 articles, of which 118 duplicates were
removed by computer software and an additional 20 duplicates were eliminated manually.
The titles, abstracts, and keywords of the remaining 433 publications were screened, and
25 records were ultimately identified for full-text review. Following full-text screening,
2 articles were excluded as they did not directly compare AA and ENZ. Hence, 23 studies
were included in this scoping review. The most common reasons for exclusion were a
lack of direct AA versus ENZ comparison, a review article format, and a lack of measured
outcomes (Figure 1).

Figure 1. PRISMA Flow Chart of studies included in the scoping review. AA = abiraterone acetate;
Enz = enzalutamide.
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3.2. Characteristics of Included Sources
The studies’ characteristics are summarized in Table 2. The studies ranged in time of
publication from 2014 to 2022, and were all observational, prospective cohort, retrospective, or population-based studies. Included studies measured a variety of metrics from
disease-specific outcomes including cancer progression, response, and survival; treatmentassociated toxicity; patient adherence; treatment duration; dose reduction; HRU; and
healthcare costs.
3.3. Comparison of Disease Progression and Survival
Better mCRPC response to ENZ was widely observed, although concomitant survival
benefit was only occasionally found. Jarimba et al. demonstrated higher response rates
with ENZ versus AA (77.1% vs. 58.1%, p = 0.016) and showed that positive response
independently reduced risk of both biochemical progression (OR: 0.248, p = 0.017) and
death (OR: 0.302, p = 0.038), but still found no significant difference in all-cause time to
death (37.5 months ENZ vs. 26 months AA, p = 0.277) [2]. Higher PSA response with ENZ
(61.6% vs. 43.8%, p < 0.004) and greater time to progression (HR 0.66; 95% CI 0.50–0.88,
p < 0.01) were recorded by Soleimani et al. [28]. Similarly, biochemical response was
attained much more quickly with ENZ (7 vs. 15.5 weeks) in the Caffo et al. study, who also
found improved biochemical PFS, with over 50% PSA reduction in 23/31 ENZ vs. 8/26 AA
patients at one month after treatment [29]. Miyake et al. demonstrated median biochemical
PFS of 11.6 months in ENZ versus 9.0 months in AA (p = 0.014) and PSA response in
70.7% of ENZ versus 53.1% of AA patients, all of which were inferior to randomized clinical
trials. PSA progression occurred in 30.5% and 54.9% of ENZ and AA patients [30]. Pilon
et al. found that AA had a 19.0% reduction in risk of death compared to placebo; the study
compared this rate to previous literature which found much higher risk reductions with
ENZ (23–37%), though statistical comparisons could not be made [31].
Three reviewed studies found a significant overall survival (OS) difference between
ENZ and AA, all in favor of ENZ. Tagawa et al. reported that ENZ patients had a 16%
lower risk of death (adjusted HR = 0.84; 95% CI, 0.76–0.84; p = 0.0012), with increased
median OS (29.63 months vs. 25.87 months) [32]. Scailteux et al. suggested a 10% improved
OS with ENZ versus AA (34.2 m vs. 31.7 m, HR 0.90, 95% CI 0.85–0.96) [33]. Demirci et al.
found longer radiographic progression-free survival (rPFS) and OS with ENZ (15 m vs. 7 m,
p < 0.001 and 29 m vs. 16 m, p = 0.027), alongside more frequent PSA decline greater than
50% (p = 0.020) [34].
Four other studies found the two therapies more comparable, although, notably,
no studies reported the superiority of AA. A mean OS of 18.9 ± 1.5 months with no
significant differences between ENZ (24 months) and AA (15 months) was found by
Al-Ali et al. [35]. Similarly, no significant difference in rPFS was observed by Banna
et al. (12.8 m ENZ vs. 17.4 m AA, p = 0.30), nor Chang et al. (9.5 m ENZ vs. 7.3 m AA,
p = 0.766) [36,37]. ENZ patients had a better biochemical response, PSA response preservation, and PSA decline, though none of these measures were statistically significant [37].
Chowdhury et al. found that time to progression was comparable and median OS was
identical for both groups (27.1 m) [38].
Age, co-morbidities, and disease stage played an important role when included in
multivariate models. Importantly, Miyake’s study reported that AA was more commonly
selected for patients with unfavorable characteristics [30]. Baseline inferior health of AA
patients was supported by Banna et al. (p = 0.04) and Demirci et al. (p = 0.016) although
refuted by Chowdhury et al., who identified de novo metastases at diagnosis in 35.0% of
AA and 42.3% of ENZ patients [36]. Behl also found that AA patients were typically older
(73.8 years vs. 72.8 years, p = 0.02).
Generally, most studies indicated superior response and sustained PFS with ENZ,
with three also reporting increased OS. The remaining studies cited low sample size as
the primary reason for a lack of significance, but still noted that ENZ seemed to improve
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disease-specific outcomes. Four studies did note a trend towards AA prescription for
patients with unfavorable disease factors, which confounds signals of ENZ superiority.
3.4. Comparison of Drug-Associated Toxicities
We reviewed included articles to uncover trends in ADEs and differences in common types of toxicities between AA and ENZ, along with associations with patient comorbidities. Jarimba et al. reported ADEs in 16.1% of AA and 11.4% of ENZ patients,
while Chowdhury et al. found that 7.1% of AA and 13.5% of ENZ patients discontinued
treatment due to toxicity, and death during the treatment period was seen in 7.2% of AA
and 11.1% of ENZ patients [2,38].
We first reviewed the association of inherent patient characteristics with treatment exposure and subsequent toxicity. Importantly, older age was not reported to affect treatment
exposure for either AA or ENZ, an important negative finding which confirms post hoc
analyses of clinical trials [39]. Similarly, body mass index or liver function did not influence
treatment exposure, although estimated glomerular filtration rate did influence exposure
to both AA and ENZ (p = 0.002 and p < 0.001) [39].
Cardiovascular toxicities following AA were noteworthy; such patterns were less
notable in ENZ patients. Lu-Yao et al. reported that AA was associated with higher
post-treatment hospitalization rates among those with pre-existing CVD. In particular,
patients with ≥3 CVD conditions had a 41% lower post-treatment hospitalization risk
when treated with ENZ compared to AA after adjustment for potential confounding
variables (IRR 0.59; 95% CI 0.44–0.79) [18]. George et al. demonstrated CVD toxicities for
both AA (HR 1.23; 95% CI 1.05–1.45) and ENZ (HR 1.10; 95% CI 1.00–1.21) compared to the
control, although the risk was higher with AA; these findings were corroborated by several
reviewed studies [40]. Stratification of specific cardiovascular toxicities demonstrated that
AA was associated with hypertension, cardiac toxicity, fluid retention, and hypokalemia,
while ENZ was associated with hypertension alone.
Central nervous system (CNS) toxicities including amnesia, cognitive disorders, confusion, and memory impairment; fatigue; and hot flashes were more common in patients
treated with ENZ [2,15,41]. Specifically, one study identified more frequent fatigue in ENZ
versus AA (18% vs. 4%, p = 0.04) [42], and another demonstrated that fatigue was the most
common reason for ENZ dose reductions (30.4%) or discontinuation (5.6%) [28]. Similarly,
a third study found that fatigue was more commonly observed in ENZ (32.3% vs. 19.4%).
Liver toxicity was very common in AA patients, affecting 11.5% of this cohort, compared
to only 5.4% of ENZ patients [30]. Another study had to withdraw two (3.1%) AA and
two (15.4%) ENZ patients for Grade 3/4 liver function impairment and Grade 3/4 fatigue,
respectively [37].
3.5. Comparison of Treatment Adherence, Dose Reduction, and Dose Modification
We sought to elucidate therapy-related factors which may impact differential adherence rates between AA and ENZ, as adherence can greatly impact outcomes in the
real-world setting. The World Health Organization has reported categories which impact patient adherence, including therapy-related toxicities and complexity of treatment,
among other factors such as patient beliefs and mental health, disease-related factors and
co-morbidities, and the clinician–patient relationship.
Generally, studies found satisfactory adherence rates for both AA and ENZ, reporting
medication possession ratios of 90% and 85% and non-adherence rates of 4.8% and 6.2% for
AA and ENZ, with no significant differences between the two [35,36,43], Importantly,
differential adherence rates did not affect OS, which was predominantly affected by preexisting co-morbidities [36,44].
Behl et al. included a Kaplan–Meier curve demonstrating that lower dose reduction
risk in AA became most evident at 3 m follow-up, with the difference becoming more
pronounced at greater follow-up periods [45]. Similarly, they reported longer exposure to
treatment with AA (7.5 ± 6.1 months vs. 6.3 ± 5.9 months; p < 0.0001). They proposed that
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high rates of fatigue with ENZ may explain lower adherence. Shore et al. similarly demonstrated more dose reductions with ENZ (16% vs. 6%), and attributed this to ADEs [41],
a finding supported by Soleimani et al. (44.8% vs. 22.9%, p < 0.001). Fewer AA versus
ENZ patients required dose reduction for reasons besides disease progression (28.8% vs.
40.8%, p = 0.04), resulting in lower dose exposures, although this did not harm outcomes.
Interestingly, time to progression was higher in ENZ patients requiring dose reduction [28].
Freedland et al. conversely found that dose reductions were not more common or
intense in ENZ versus AA. Moreover, dose reductions were seen in 64.4% of all study
patients and were associated with 8.8% increased risk of biochemical progression. Dose
reductions are relevant given that the combination of ENZ with a CYP2C8 inhibitor can
increase ENZ levels by 2.2-fold, thereby potentially requiring a lower dose [46].
Finally, Pilon et al. found treatment duration was significantly higher with AA
(18.3 m vs. 14.2 m, p < 0.001), and AA patients experienced fewer discontinuations (HR = 0.73;
p = 0.004) across a 24 m span [31]. Two studies actually reported a longer median treatment
duration in ENZ versus AA (19.7 vs. 8.8 m and 9.93 m vs. 8.47 m, p = 0.0008) [32,47].
Table 2. Selected study characteristics.
Authors

Study Design

Population Characteristics

Outcomes Reported

Al-Ali, B. et al. (2018) [35]

Retrospective
population-based database

CRPC patients (N = 457),
mean age 74.4 y, AA N = 195,
ENZ N = 139

OS, MPR, treatment duration,
length of hospital stay

Banna, G. et al. (2020) [36]

Observational prospective
cohort

mCRPC patients (N = 58),
median age 76 y, AA N = 22,
ENZ N = 36

Cancer response, OS,
radiographic PFS, adherence

Behl, A. et al. (2017) [45]

Retrospective
population-based database

mCRPC patients, AA
N = 2591, ENZ N = 807

OS, MPR, dose reduction

Caffo, O. et al. (2014) [29]

Observational prospective
cohort

Progressive CRPC patients,
AA N = 26, ENZ N = 31

Cancer response, cancer
progression, toxicities

Chang, L. et al. (2019) [37]

Retrospective
single-institutional cohort

mCRPC patients with prior
docetaxel treatment, AA
N = 64, ENZ N = 13

Cancer response, OS, PFS,
toxicities

Chowdhury, S. et al. (2020)
[38]

Retrospective
population-based database

mCRPC patients, AA N = 754,
ENZ N = 227

Time to progression, OS,
treatment duration

Cindolo, L. et al. (2019) [44]

Retrospective
population-based database

mCRPC patients, AA N = 109,
ENZ N = 14

Drug persistence, adherence

Crombag, M. et al. (2019) [39]

Retrospective
single-institutional cohort

CRPC patients, AA N = 71,
ENZ N = 64

Drug exposure by
co-morbidity

Demirci, A. et al. (2021) [34]

Retrospective
multi-institutional cohort

mCRPC patients (N = 250)

Treatment response,
radiographic PFS, OS

Freedland, S. et al. (2021) [46]

Retrospective
population-based database

mCRPC patients (N = 6069)

Dose reduction

George, G. et al. (2021) [40]

Retrospective
population-based database

CRPC patients, AA N = 1310,
ENZ N = 3579

Toxicities (cardiovascular)

Hu, J. et al. (2021) [15]

Retrospective
population-based database

mCRPC patients (N = 2183),
AA N = 1773, ENZ N = 410

Hospitalizations, toxicities
(cardiovascular)

Jarimba, R. et al. (2021) [2]

Retrospective
single-institutional cohort

mCRPC patients (N = 91), AA
N = 56, ENZ N = 35

Treatment response, PFS,
toxicities

Lu-Yao, G. et al. (2019) [18]

Retrospective
population-based database

CRPC patients, AA N = 2845,
ENZ N = 1031

Mortality, hospitalizations,
toxicities (cardiovascular)
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Table 2. Cont.
Authors

Study Design

Population Characteristics

Outcomes Reported

Miyake, H. et al. (2017) [30]

Retrospective
single-institutional cohort

mCRPC patients (N = 280),
AA N = 113, ENZ N = 167

Treatment response, cancer
progression, toxicities

Pilon, D. et al. (2017) [31]

Retrospective
population-based database

mCRPC patients, N = 3398,
AA N = 2591, ENZ N = 807

Treatment discontinuation,
treatment duration

Ramaswamy, K. et al. (2020)
[48]

Retrospective
population-based database

mCRPC patients (N = 3174),
AA N = 1945, ENZ N = 1229

HRU, costs

Salem, S. et al. (2017) [42]

Retrospective
single-institutional cohort

mCRPC patients (N = 189),
AA N = 76, ENZ N = 113

Treatment duration, dose
reduction, toxicities

Scailteux, L. et al. (2020) [33]

Retrospective
population-based database

CRPC patients (N = 10,308),
AA N = 6585, ENZ N = 3723

OS

Schultz, N. et al. (2018) [47]

Retrospective
population-based database

mCRPC patients, AA
N = 2310, ENZ N = 920

Treatment duration,
hospitalizations, HRU, costs

Shore, N. et al. (2019) [41]

Prospective Phase IV
surveillance study

mCRPC patients with
exclusion of those with prior
chemotherapy, seizure
disorder, dementia, or
substance abuse, N = 92, AA
N = 46, ENZ N = 46

Dose reduction, toxicities

Soleimani, M. et al. (2021) [28]

Retrospective
single-institutional cohort

mCRPC patients aged ≥ 80
years (N = 278), AA N = 153,
ENZ N = 125

Treatment response, cancer
progression, dose reduction

Tagawa, S. et al. (2021) [32]

Retrospective
population-based database

mCRPC patients, AA
N = 1229, ENZ N = 1945

OS, treatment duration,
toxicities

Note: AA = abiraterone acetate; Enz = enzalutamide; mCRPC = metastatic castration resistant prostate cancer;
MPR = medication possession ratio; OS = overall survival; PFS = progression free survival; HRU = healthcare
resource utilization.

3.6. Comparison of Resource Utilization, Hospitalization, and Cost
For cohorts where disease-specific outcomes, co-morbidity interactions, or toxicity
sensitivities are not clearly different between AA and ENZ, systemic factors such as total
cost or HRU might inform treatment choice. These factors can impact quality of life and
public health, but are not commonly studied as relevant outcomes, and, hence, only three
studies primarily reported such data.
Al-Ali et al. indicated the importance of HRU as an outcome of relevance by remarking
that only 9.4% of study patients were never hospitalized, and patients spent an average of
13% of their remaining life span in the hospital. Hospital stays were generally longer with
AA versus ENZ (39.4 ± 36.8 days vs. 26.3 ± 25.8 days) [35]. Increased costs were largely
linked to risk of hospitalizations or healthcare visits and length of hospital stays. Of note,
these data were from Austria, and exact costs may differ across countries, particularly in
the United States, although relative comparisons likely remain consistent.
Ramaswamy et al. found fewer all-cause outpatient or pharmacy visits and costs per
patient per month (PPPM) for ENZ patients in the United States. The ENZ cohort experienced fewer all-cause inpatient (2.51 vs. 2.86, p < 0.0001) and PCa-related outpatient visits
(0.86 vs. 1.03, p < 0.0001). This corresponded with lower all-cause (USD 2588 vs. USD 3115,
p < 0.0001) and PCa-related (USD 1356 vs. USD 1775, p < 0.0001) outpatient costs PPPM.
Total medical plus pharmacy costs were also lower with ENZ (USD 8085 vs. USD 9092,
p = 0.0002 and USD 6321 vs. USD 7280, p < 0.0001). Overall, emergency room, cancerrelated visit, cancer-related pharmacy, and all-cause costs were all lower with ENZ, and a
yearly cost benefit of USD 12,000 was identified [48]. The authors also noted that differences in HRU and cost were significantly larger than those expected from clinical trials,
attributing the discrepancy to higher HRU by patients who were ineligible for trials.
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Schultz et al. supported these findings. ENZ patients reported fewer all-cause inpatient
admissions (IRR 0.87; 95% CI 0.76–0.99), days of hospitalization (IRR 0.84; 95% CI 0.70–1.02),
and outpatient visits (IRR 0.94; 95% CI 0.90–0.98), alongside fewer PCa-related outpatient
visits (IRR 0.92; 95% CI 0.87–0.96) versus AA. Furthermore, within 3 m of treatment initiation, ENZ patients visited the emergency department for PCa-related concerns at 28% lower
rates (adj OR 0.72; 95% CI 0.53-0.98) and were admitted as inpatients at 24% lower rates (adj
OR 0.76; 95% CI 0.57-1.02). Although monthly pharmacy costs were USD 545 higher for
ENZ (p < 0.001), this drug expense was negated by lower total healthcare costs compared to
AA. Upon adjusted differences of USD 485 for total pharmacy costs (p < 0.001) and USD 834
for index drug costs (p < 0.001), this resulted in adjusted cost savings of USD 28 (p = 0.009)
for emergency department visits and USD 122 (p = 0.024) for inpatient admissions with
ENZ [47].
Focusing on cardiovascular risk, two additional studies further clarified differences in
HRU. AA patients had increased risk of all-cause (HR 1.26; 95% CI 1.04–1.53; p = 0.019),
CVD-related (HR 1.82; 95% CI 1.09–3.05, p = 0.022), and heart failure-related (HR 2.88;
95% CI 1.09–7.63) hospitalizations [15]. As previously mentioned, patients with three or
more CVDs had a 41% lower hospitalization rate when administered ENZ versus AA
(IRR = 0.59; 95% CI 0.44–0.79) [18].
4. Discussion
This review found notable differences in treatment outcomes following AA versus
ENZ among patients with mCRPC (Table 3). In general, ENZ is associated with more
favorable survival and disease control. Three studies demonstrated better survival following ENZ compared with AA [32–34]. Several studies showed a similar trend but did not
reach statistical significance, primarily due to low sample sizes during subgroup analyses
performed to exclude confounding patient factors. Patients with pre-treatment risk factors
or lower baseline prognosis more likely received AA. Nonetheless, most studies agreed
that ENZ patients demonstrate increased biochemical or radiographic response. Although
significance is difficult to achieve given variable patient populations and small cohort sizes,
it appears that ENZ is demonstrably superior in disease control [4,49].
Table 3. Summary of findings.
Outcomes

AA

ENZ

Disease progression and survival
Higher biochemical response rate [28–31]

X

Improved biochemical progression-free survival [29–31]

X

Improved OS or rPFS [33–35]

X

Comparable OS or rPFS [36–39]
Baseline inferior patient health [31,35,37,46]

Equal
X

Drug-associated toxicities
Higher cardiovascular toxicities [15,18,41]

X

Higher CNS toxicities [15,28,42]

X

Increased fatigue [15,28,29,38,42,43]

X

Increased hepatotoxicity [31,38]

X

Treatment adherence, dose reduction, and dose modification
Adherence [36,37,44]
Increased dose reduction [32,42,46]

Equal
X
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Table 3. Cont.
Outcomes

AA

ENZ

HRU, hospitalization, and cost
Increased length of hospital stay [36]

X

Increased all-cause cost [49]

X

Increased HRU, visits, or admissions [48,49]

X

Increased pharmacy costs [48]

X

Note: AA = abiraterone acetate; ENZ = enzalutamide.

A previous review of clinical trials which indirectly compared AA and ENZ found that
OS and cancer progression were slightly better for the latter, corroborating our findings. It
also reported significant superiority of ENZ for secondary measures including biochemical
response, biochemical progression, and rPFS. However, this study similarly lost significance
upon subgroup analysis [3]. Another review of trials supported these findings, but without
direct comparison of the two drugs, potential translation to treatment choice algorithms
remains limited [50].
Universally, as expected, disease-specific outcomes were inferior in included studies
when compared to clinical trials. This can be attributed to patient selection and strict
exclusion criteria eliminating co-morbid patients from trials [51]. One clinical trial review
found an OS advantage of 4.6 m and 4.8 m for AA and ENZ [52]. Without NHTs, median
OS of metastatic castration-resistant PCa is 14 m, meaning these drugs can extend survival
by approximately 35% [53].
It is important to note that clinical trials certainly hold value compared to retrospective
analyses, where the patient cohort is extremely heterogeneous and may include patients
with PCa at different timepoints in the natural history of disease. Hence, future comparative
studies with different risk sub-groups may hold utility in analyzing treatment choice for the
real-world PCa population. Larger population-based studies which can control for patient
heterogeneity may also robustly demonstrate a difference in efficacy and CRPC response.
Despite recent approvals of these drugs in castration-sensitive PCa, this scoping review
did not identify any study with such patients, indicating further study is also essential in
this setting.
Interestingly, two studies reported differences in AA outcomes based on race and
ethnicity, finding that African American men experienced improved PSA response and OS
compared with non-Hispanic White men [54,55]. These findings warrant further analyses
of the differential impacts of race and ethnicity on AA versus ENZ outcomes to determine
the utility of these patient-specific traits in treatment assignment algorithms. Reduced
PFS following AA was exhibited in patients with diabetes, although this has not yet been
reported in ENZ [56]. Further research is necessary to clarify whether patients with preexisting diabetes may benefit more from one treatment versus another.
4.1. Consideration of Treatment Toxicities
This review found significant and noteworthy differences in drug-associated toxicities
between AA and ENZ. Although both drugs demonstrated largely similar rates of drugrelated AEs and high-grade AEs, the specific toxicities differed. Therefore, pre-existing
conditions may be considered when assigning patients to a therapy.
In the clinical trial setting, AA was associated with fluid retention, hypertension,
and hypokalemia [47]. Because clinical trials often exclude patients with significant comorbidities, we believed that compiling ADEs from various smaller studies would clarify
the common toxicities that clinicians may expect and monitor in the real world. We found
that while types of toxicities largely remained consistent, overall ADEs occurred more
frequently outside the trial setting.
Importantly, our analysis demonstrated that age and liver function do not appear to
influence treatment exposure. However, AA is associated with a higher risk of liver toxicity.
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In the real-world, most men with pre-existing impaired liver function should avoid AA.
Drug–drug interactions were not analyzed in this review but comprise a significant source
of toxicity. As previously described, ENZ exposure can increase notably with concurrent
CYP2C8 inhibitors, making this an important point of future inquiry.
Although both AA and ENZ have been shown to increase major cardiovascular events
requiring hospitalization [18,57], namely, AA was shown to confer significantly more
cardiovascular toxicities. One meta-analysis of clinical trials reported that AA confers a
2.2-fold risk of cardiovascular toxicity (RR 2.2; 95% CI 1.60–3.27) through post-treatment
hospitalizations across all CVD categories examined, although mortality differences were
not observed. This risk was not seen with ENZ (RR = 1.32; 95% CI: 0.85–2.06) [18]. Elucidating interactions with CVDs is important, as two-thirds of Medicare patients treated
with NHTs had pre-existing CVD conditions, and these patients experience 23–37% higher
mortality [18]. Further study is needed to evaluate whether patients with several CVD
conditions will have more favorable outcomes with ENZ than with AA.
The toxicities of prednisone, which is typically administered alongside AA, must
also be considered, as long-term use of corticosteroids have well-elucidated detrimental
effects [8]. Mineralocorticoid-related AEs, including hypertension, fluid retention, and
hyperkalemia, are also associated with AA [3,5,53]. AA may be less advisable in patients
with CHF, renal failure, or metabolite disturbances [18].
Conversely, our results confirmed that fatigue is a well-established and commonly
observed toxicity of ENZ, alongside other CNS toxicities such as amnesia, confusion, and
cognitive disorders. Patients with neurological risk factors may be less suited for ENZ
treatment, and those receiving ENZ may be closely monitored, particularly if they have a
known seizure disorder, brain metastases, or brain injury.
Many of these findings have been demonstrated in clinical trials, although a direct
comparison between AA and ENZ has not been made. As expected, fatigue with ENZ was
more common in our review of real-world studies than in trials [58].
4.2. Differences in Systemic Healthcare Quality Metrics
Our study unequivocally found that ENZ resulted in reduced total healthcare costs
and HRU, with cost-related studies focusing on the United States and HRU-related analyses
being consistent across countries. Although ENZ was more expensive in direct pharmacy
costs, ENZ patients were less likely to require other healthcare services, and, hence, incurred
fewer net costs. Similarly, HRU was significantly lower for ENZ patients, with significantly
fewer post-treatment outpatient, inpatient, and emergency room visits. Further study is
necessary to evaluate whether this financial toxicity affects accessibility and treatment
outcomes for patients based on socioeconomic and geographic factors.
In terms of drug costs alone, a previous cost effectiveness analysis found that AA
has a 28% lower cost than ENZ [59]. This study assumed that treatment duration and
OS were shorter in AA. Even after accounting for treatment durations or recommended
treatment-specific monitoring costs, AA was cheaper. However, total cost incurred is more
relevant than pharmacy expenses alone, and total costs are consistently lower with ENZ.
A previous study of oral targeted therapies found that both AA and ENZ precipitated
greater all-cause healthcare costs than older agents, namely docetaxel and prednisone [60].
Numerous other cost-effectiveness analyses have corroborated this finding. All-cause
monthly total healthcare costs for patients receiving NHTs were estimated at approximately
15,000 (2017 USD).
Although secondary hormonal therapies may delay disease progression, they often
confer significant AEs, which may increase costs and HRU while reducing quality of
life. One study reported CNS ADEs in nearly 46% of ENZ patients [61]. Our review
demonstrates that ENZ-associated fatigue and other ADEs impacted adherence and dose
reduction rates but did not increase costs or HRU when compared to AA-associated ADEs.
As discussed, because AA is administered concomitantly with prednisone, it was expected
that AA would result in increased healthcare needs.
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Notably, post-NHT HRU cannot be entirely attributed to drug-related adverse effects.
This patient cohort experiences several complications related to mCRPC itself, including
severe skeletal-related events (SREs) such as spinal cord compressions and fractures due to
bony metastases. Importantly, both AA and ENZ have been shown to significantly delay
SREs, although bone modulating agents are now recommended in combination with either
of these antiandrogens to further reduce incidence. Nonetheless, PCa-related complications
such as SREs can contribute to post-NHT HRU, and differences in their frequency between
AA and ENZ should be analyzed in future comparisons [62,63].
Direct healthcare costs of castration-resistant PCa range from USD 2474 to USD 67,957
annually. These costs increase five-fold upon metastasis, and HRU increases 1.5–2.5-fold [60].
Given the significant cost and healthcare need, it is important to assign treatments which
minimize healthcare burdens at the patient and systems-based levels. These measures are
important systems-based considerations when determining treatment choice, particularly
when disease-specific outcomes may appear equivocal and patient history may not directly
exclude one of the drug options.
4.3. Strengths and Limitations
This study had several strengths. The review utilized a strong, transparent methodology based upon a previously registered protocol. A broad search was conducted in four
major databases, and studies were evaluated independently by three reviewers. Finally, a
multidisciplinary team was involved throughout the study, including expert clinicians who
informed this study’s discussion of clinical implications. Nonetheless, this scoping review
has various limitations, including the exclusion of abstracts and non-English articles. Given
the retrospective nature of included studies, patient cohorts were heterogenous. Although
individual studies performed multivariate adjustments to adjust for co-morbidities and
other modulating factors, the full extent of inter-cohort differences cannot be elucidated in
a scoping review, and, hence, these findings should be interpreted with caution. A further
limitation includes the lack of information surrounding patient diversity, including data on
patient race and ethnicity, which limits broad applicability. Finally, synthesis of results and
summative statistical analysis was limited given the broad definition of outcomes and the
relatively small amount of data available for each individual outcome.
5. Conclusions
This is the first scoping review to compare the treatment outcome of AA vs. ENZ
amongst mCRPC patients. Existing retrospective and real-world studies indicate that AA
and ENZ have profoundly differing effects based on patient risk factors, as AA is associated
with notable cardiovascular toxicities while ENZ has neurological adverse effects and
fatigue. AA demonstrates poorer systemic outcomes including HRU and cost, while it
shows superior treatment adherence. Finally, ENZ offers faster and more frequent disease
response, and select studies demonstrated improved survival, although these outcomes are
still unclear. Real-world outcomes data with both agents were inferior to results seen in
clinical trials. These differences may become increasingly relevant as many AA and ENZ
users have a higher comorbidity burden than those in clinical trials and NHT indications
are expanding to earlier disease stages [64]. The results of this scoping review suggest that
further research comparing patient-specific and systemic measures following AA and ENZ
therapy is needed. Further study may inform an evidence-based, patient-centered clinical
decision making algorithm to optimize PCa patient outcomes and experiences.
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